MIAKER Developments was founded in 2019, and has its headquarters located in San Sebastian, Spain. It is an independent small Contract Research Organization formed by industry and academic experts with long- term experience in preclinical and clinical research.
MIAKER Bioassays is MIAKER Developments ́ arm that provides services in an early phase of Drug Discovery programs, specialized in Screening of New Molecular Entities (NMEs) or Repurposed Molecular Entities (RMEs). MIAKER Bioassays introduces a novel platform, PLATFLY™, for both, in vitro and in vivo, Medium size Throughput Screening of chemicals at early phase of development, understanding their potential therapeutic efficacy and toxicity in validated models of neurological diseases. We use Droshophila melanogaster avatars human-disease genotypes with perfectly studied phenotypes.
We were born with the intention to support Startups, Small and Mid-Sized Pharmaceutical and Biotech Companies with their development of novel drugs targeting unmet neurodegenerative and neuromuscular diseases, providing disease specific models and accurate, measurable methods for best candidates selection.
Our team is composed by highly experienced researchers in new models of neurological disorders, in drug discovery of new drugs targeting these models, and by expert clinicians in different neurological disorders such as: Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia and a variety of Muscular Dystrophies.
